Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Seres Therapeutics (MCRB) Shares Outstanding (Diluted Average) (2020 - 2025)

Seres Therapeutics (MCRB) has disclosed Shares Outstanding (Diluted Average) for 6 consecutive years, with $8.9 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Diluted Average) rose 14.16% to $8.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.9 million through Dec 2025, up 14.16% year-over-year, with the annual reading at $8.9 million for FY2025, 14.16% up from the prior year.
  • Shares Outstanding (Diluted Average) hit $8.9 million in Q4 2025 for Seres Therapeutics, up from $8.7 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $152.6 million in Q3 2024 to a low of $6.4 million in Q4 2023.
  • Historically, Shares Outstanding (Diluted Average) has averaged $78.0 million across 5 years, with a median of $92.2 million in 2022.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): surged 40.79% in 2023 and later tumbled 94.2% in 2024.
  • Year by year, Shares Outstanding (Diluted Average) stood at $91.7 million in 2021, then grew by 17.86% to $108.1 million in 2022, then crashed by 94.08% to $6.4 million in 2023, then rose by 21.4% to $7.8 million in 2024, then increased by 14.16% to $8.9 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for MCRB at $8.9 million in Q4 2025, $8.7 million in Q1 2025, and $7.8 million in Q4 2024.